Laurie H. Glimcher

Laurie H. Glimcher

Auto-generated profile, based on publicly available information

Laurie H. Glimcher

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Cell
Verified
Journal Article
Closed access
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
SBSarah E. Bettigole
Sarah E. Bettigole
LGLaurie H. Glimcher
Laurie H. Glimcher

10 October 2018 in Nature
Verified
Journal Article
Open access
PDF file
MSMinkyung Song
Minkyung Song
TSTito A. Sandoval
Tito A. Sandoval
CCChang-Suk Chae
Chang-Suk Chae
SCSahil Chopra
Sahil Chopra
CTChen Tan
Chen Tan
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
Tumours evade immune control by creating hostile microenvironments that perturb T cell metabolism and effector function1,2,3,4. However, it remains unclear how intra-tumoral T cells integrate and interpret metabolic stress signals. Here we report that ovarian cancer—an aggressive malignancy that is refractory to standard treatments and current immunotherapies5,6,7,8—induces endoplasmic reticulum stress and activates the IRE1α–XBP1 arm of the unfolded protein response9,10 in T cells to control their mitochondrial respiration and anti-tumour function. In T cells isolated from specimens collected from patients with ovarian cancer, upregulation of XBP1 was associated with decreased infiltration of T cells into tumours and with reduced IFNG mRNA expression. Malignant ascites fluid obtained from patients with ovarian cancer inhibited glucose uptake and caused N-linked protein glycosylation defects in T cells, which triggered IRE1α–XBP1 activation that suppressed mitochondrial activity and IFNγ production. Mechanistically, induction of XBP1 regulated the abundance of glutamine carriers and thus limited the influx of glutamine that is necessary to sustain mitochondrial respiration in T cells under glucose-deprived conditions. Restoring N-linked protein glycosylation, abrogating IRE1α–XBP1 activation or enforcing expression of glutamine transporters enhanced mitochondrial respiration in human T cells exposed to ovarian cancer ascites. XBP1-deficient T cells in the metastatic ovarian cancer milieu exhibited global transcriptional reprogramming and improved effector capacity. Accordingly, mice that bear ovarian cancer and lack XBP1 selectively in T cells demonstrate superior anti-tumour immunity, delayed malignant progression and increased overall survival. Controlling endoplasmic reticulum stress or targeting IRE1α–XBP1 signalling may help to restore the metabolic fitness and anti-tumour capacity of T cells in cancer hosts.

21 May 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RXRen Xu
Ren Xu
AYAlisha Yallowitz
Alisha Yallowitz
AQAn Qin
An Qin
ZWZhuhao Wu
Zhuhao Wu
DSDong Yeon Shin
Dong Yeon Shin
MGMatthew B. Greenblatt
Matthew B. Greenblatt

13 May 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
HDHan Dong
Han Dong
NANicholas M. Adams
Nicholas M. Adams
YXYichi Xu
Yichi Xu
JCJin Cao
Jin Cao
DADavid S. J. Allan
David S. J. Allan
LGLaurie H. Glimcher
Laurie H. Glimcher

13 June 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HDHan Dong
Han Dong
JHJames Dongjoo Ham
James Dongjoo Ham
GHGuangan Hu
Guangan Hu
GXGuozhu Xie
Guozhu Xie
JVJuliana Vergara
Juliana Vergara
RRRizwan Romee
Rizwan Romee
Acute myeloid leukemia (AML) remains a therapeutic challenge, and a paucity of tumor-specific targets has significantly hampered the development of effective immune-based therapies. Recent paradigm-changing studies have shown that natural killer (NK) cells exhibit innate memory upon brief activation with IL-12 and IL-18, leading to cytokine-induced memory-like (CIML) NK cell differentiation. CIML NK cells have enhanced antitumor activity and have shown promising results in early phase clinical trials in patients with relapsed/refractory AML. Here, we show that arming CIML NK cells with a neoepitope-specific chimeric antigen receptor (CAR) significantly enhances their antitumor responses to nucleophosphmin-1 (NPM1)-mutated AML while avoiding off-target toxicity. CIML NK cells differentiated from peripheral blood NK cells were efficiently transduced to express a TCR-like CAR that specifically recognizes a neoepitope derived from the cytosolic oncogenic NPM1-mutated protein presented by HLA-A2. These CAR CIML NK cells displayed enhanced activity against NPM1-mutated AML cell lines and patient-derived leukemic blast cells. CAR CIML NK cells persisted in vivo and significantly improved AML outcomes in xenograft models. Single-cell RNA sequencing and mass cytometry analyses identified up-regulation of cell proliferation, protein folding, immune responses, and major metabolic pathways in CAR-transduced CIML NK cells, resulting in tumor-specific, CAR-dependent activation and function in response to AML target cells. Thus, efficient arming of CIML NK cells with an NPM1-mutation-specific TCR-like CAR substantially improves their innate antitumor responses against an otherwise intracellular mutant protein. These preclinical findings justify evaluating this approach in clinical trials in HLA-A2 + AML patients with NPM1c mutations.

19 July 2019 in Science
Verified
Journal Article
Closed access
PDF file
SCSahil Chopra
Sahil Chopra
PGPaolo Giovanelli
Paolo Giovanelli
PAPerla Abigail Alvarado-Vazquez
Perla Abigail Alvarado-Vazquez
SASara Alonso
Sara Alonso
MSMinkyung Song
Minkyung Song
JCJuan R. Cubillos-Ruiz
Juan R. Cubillos-Ruiz
A “sUPR” target for pain management?: The unfolded protein response (UPR) is initiated when unfolded or misfolded proteins accumulate in the endoplasmic reticulum. One highly conserved arm of the UPR, the IRE1α–XBP1 signaling pathway, also plays a role in various other UPR-independent processes, including hypoxia, angiogenesis, and inflammation. Chopra et al. report that this pathway additionally regulates the production of two molecules, cyclooxygenase 2 and microsomal prostaglandin E synthase 1, that help mediate inflammation-induced pain (see the Perspective by Avril and Chevet). When elements of the IRE1α–XBP1 signaling pathway were knocked out, pain behaviors were reduced in two different mouse models of pain. Targeting this pathway may result in improved pain management therapies. Science , this issue p. eaau6499 ; see also p. 224